<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300062</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00035-34</org_study_id>
    <nct_id>NCT04300062</nct_id>
  </id_info>
  <brief_title>Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer</brief_title>
  <acronym>REBIMMUNE</acronym>
  <official_title>Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study aims to collect tumor tissue at the moment of progression under
      Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital,
      in order to insure later study on molecular mechanism involving the progression of NSCLC and
      SCLC under ICI.

      The further analysis of research will be performed in the EA 4340 unity, Biomarkers and
      Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of creation a tumor tissue bank, all sampling will be stored in the
      biological resources center of Ambroise Paré hospital.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of specific histomolecular resistance</measure>
    <time_frame>At the end of study, up to 2 years</time_frame>
    <description>Banking of tumor samples at progression with immune checkpoint inhibitor (ICI) in lung cancer, to evaluate the incidence of specific histomolecular resistance mechanisms to ICI by immunohistochemistry and molecular testing.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Rebiopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rebiopsy</intervention_name>
    <description>Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.</description>
    <arm_group_label>Rebiopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed NSCLC or SCLC;

          -  Patient treated priorly by ICI and progressed under ICI;

          -  Have provided written informed consent for the study;

          -  Be &gt;/= 18 years of age on day of signing informed consent.

        Exclusion Criteria:

          -  Patient under guardianship or curatorship;

          -  Unable to provide written informed consent for the study;

          -  Technical impossibility to carry out tissular rebiopsy under local anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne Giroux Leprieur, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Etienne Giroux Leprieur, MD, PhD</last_name>
    <phone>+33 1 49 09 58 02</phone>
    <email>etienne.giroux-leprieur@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Giroux Leprieur E, Dumenil C, Julie C, Giraud V, Dumoulin J, Labrune S, Chinet T. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer. 2017 Jun;78:16-23. doi: 10.1016/j.ejca.2016.12.041. Epub 2017 Apr 11. Review.</citation>
    <PMID>28407528</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>rebiopsy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

